Concord Biotech Limited (BOM:543960)
India · Delayed Price · Currency is INR 1,304.10
-0.80 (-0.06%)
At close: Jul 10, 2026
Concord Biotech Stock Forecast
Stock Price Forecast
According to 5 analysts polled by S&P Global, Concord Biotech stock has a consensus rating of "Buy" and an average price target of ₹1,216. The average 1-year stock price forecast is 6.76% lower than the current stock price, while the lowest is ₹1,020 (-21.79%) and the highest is ₹1,400 (+7.35%).
Price Target: ₹1,216 (-6.76%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Concord Biotech stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Apr '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 2 | 2 | 2 | 2 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 5 | 5 |
Financial Forecast
Revenue This Year
12.63B
from 10.55B
Increased by 19.69%
Revenue Next Year
14.82B
from 12.63B
Increased by 17.34%
EPS This Year
32.11
from 25.01
Increased by 28.37%
EPS Next Year
41.07
from 32.11
Increased by 27.89%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 13.1B | ||
| Avg | 12.6B | ||
| Low | 12.1B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 24.1% | ||
| Avg | 19.7% | ||
| Low | 15.0% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 34.00 | ||
| Avg | 32.11 | ||
| Low | 29.40 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 35.9% | ||
| Avg | 28.4% | ||
| Low | 17.5% |